Skip to content
In the first full quarter under the coronavirus pandemic, Snap revenue and DAUs grew — but the latter wasn’t enough to meet expectations....
Microsoft Corporation (NASDAQ: MSFT) is poised to report strong fourth-earnings Wednesday, according to tech analysts.Wedbush's Daniel Ives maintained an Outperform rating on Microsoft with a $260 price target, while Jefferies' Brent Thill maintained a Buy rating and raised the price target from $200 to $240.Azure Key To Microsoft's Results: During the June quarter, there was "robust cloud deal activity" around Microsoft's Azure, Ives said in a Monday note.The work from home environment created by COVID-19 is "is further catalyzing more enterprises to make the strategic cloud shift with Microsoft across the board," the analyst said.Some firms are accelerating their partnerships with Microsoft by six to 12 months, he said. "Azure's cloud momentum is still in its early days," and Microsoft "is the core cloud name" in the trend of cloud deployments, Ives said. View more earnings on MSFTThe number of workloads in the cloud could rise from 33% today to 55%...
Typically, when a public company reports earnings, it highlights a positive in its release, no matter how much money it lost in the previous three months. But on Tuesday, United Airlines did not spin, telling investors it recently completed "the most difficult financial quarter in its 94-year-history." United reported a net loss of $1.6 billion, […]...
(Bloomberg) -- President Donald Trump warned that the U.S. coronavirus outbreak will probably worsen before improving, and encouraged Americans to wear masks and avoid risky behavior.The Centers for Disease Control and Prevention found that far more people were infected than previously reported in several corners of the U.S. California’s cases topped 400,000, while Texas had its second-deadliest day.Covid antibodies in patients with mild symptoms fade quickly, raising concerns that their immunity from a future infection may not last very long, researchers said in the New England Journal of Medicine. European regulators are preparing for the possibility of approving a vaccine this year after a flurry of promising results, even as comments from the U.K.’s chief medical officer reflected uncertainty in the scientific community.Key Developments:Global Tracker: Cases pass 14.7 million; deaths top 611,000Economists say $1 trillion needed to avert U.S. disasterSeniors weigh long-term care plans against Covid-19 risksThe inside story of how...
JMP Securities analyst Joseph Osha downgraded shares of Tesla to market perform from market outperform ahead of the company’s second-quarter results, as he thinks any intermediate-term success “is now fairly reflected in the stock price.” Osha joins The Final Round to discuss his call, and what to expect from Tesla’s earnings report on Wednesday....
